Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MyoKardia, Inc.

http://www.myokardia.com

Latest From MyoKardia, Inc.

Third Rock Thinks Its Model Reassures Investors In Difficult Times

New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.

Financing Business Strategies

Keeping Track: Mycovia Vivjoa, BMS Camzyos Approvals Bring FDA’s 2022 Novel Drug Tally To 12

US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.

US FDA Performance Tracker Drug Review

BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use

Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label. 

Launches Cardiovascular

Four Major Approval Decisions To Watch Out For In Q2

Having looked at four prominent drug candidates which are expecting important top-line data this quarter, with the help of Biomedtracker's Q2 Outlook Report, we take a look at four other assets that could soon break into the US market, from infectious diseases to diabetes.

Drug Review Companies
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • ADMET
      • Genomics-Proteomics
UsernamePublicRestriction

Register